This provocative article does not mince words. The authors argue that genome sequencing and scRNA-seq yield findings challenging the notion that cancer is a ‘genetic disease’: "... the cancer research community has abandoned deep thinking for deep sequencing" 1/n

A European history of prostate cancer radiotherapy, with gratitude to the always amazing Prof David Dearnaley 📚 Bedtime reading for #Prostate radoncs: oncopedia.wiki/contributions/… The Royal Marsden NHS Foundation Trust The ICR ESOncology #ProstateCancer

Sensory neurons shape local macrophage identity via TGF-β signaling Immunity cell.com/immunity/fullt…

A scientific giant and guiding light. David made just as much impact via his institutional leadership of national scientific policy as he did with his Nobel-winning discovery of reverse transcriptase. I treasure our conversations and his wisdom. RIP nytimes.com/2025/09/07/sci…

This article suggests that TF binding is determined by the sum of multiple, overlapping binding sites. Thus, competition between paralogous TFs for shared high-affinity binding sites may be influences by flanking nucleotides from overlapping, lower-affinity binding sites. 🧵

So interesting and so many unexpected findings here. NK cells, really? 🧐🤷🏻‍♀️

Lifelong social experiences shape brain aging and dementia. In our new Nature Communications with ReDLat Dementia, we studied these processes across Latin America. We developed a multidimensional social exposome (MSE) metric that shows strong links with multiple brain health indicators.

Proud to share our first TRACERx cancer study integrating epigenomics + genomics in NSCLC as co-drivers of tumor evolution. Led by not me but by the wonderful Nnennaya Kanu, Francisco Gimeno-Valiente, Carla Castignani, Peter Van Loo

Circulating Tumor Cells: Mechanistic drivers of metastasis & biomarker promise 🌊 Intravasation via EMT/VEGF; clusters = 25–50× ↑ metastasis 🔀 Lineage plasticity (epithelial ↔ mesenchymal ↔ neuroendocrine) 🛡️ Platelets & neutrophils shield CTCs; PD-L1+ escape 🧬

Excited to share our work in The EMBO Journal! shorturl.at/zXNyn For decades, we’ve known that cells dismantle & rebuild the nuclear envelope in coordination with spindle poles. But what is the relevance of this coordination? Follow this thread to find out 👇

As of now, I am only ordering bpMRI for early detection of prostate cancer. And for AS patients if DCE added nothing on initial MRI (which is likely everybody). This is a good thing well done PRIME team. Saves time, money, plus deals with concerns about “gadolinium brain”.

Olanzapine, when tolerated (I usually dose escalate from 2.5 mg) should be standard for cachexia, appetite, nausea. Still seeing megace, mirtazapine recommended despite essentially no evidence. We need more supportive onc education for our hem inc practitioners and fellows.

Nature research paper: Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours go.nature.com/48fgPRb

Great list of supportive interventions. Also cryotherapy for Oxaliplatin, not just Taxanes. Significant fears of cold reaction, yet well tolerated in many patients we use for and many others and now has a study supporting use. esmoopen.com/article/S2059-…

Online Now: Extrachromosomal DNA associates with nuclear condensates and reorganizes chromatin structures to enhance oncogenic transcription dlvr.it/TN8xgq

La UNAM lamenta el fallecimiento de Julieta Fierro, #OrgulloUNAM, investigadora del Instituto de Astronomía, integrante del Sistema Nacional de Investigadoras e Investigadores, en su nivel más alto, y de la Academia Mexicana de la Lengua. Con su voz y dedicación acercó la ciencia

Fairy FTW?! 🤯

Abiraterone 250mg vs. 1000mg? Multiple studies continue to show similar efficacy and ⬇️ cost (though through Mark Cuban Cost Plus Drug Company Mark Cuban, cost has gone ⬇️ significantly…), should the lower dose be the SoC in CRPC and higher dose be used as a back-up? #OncTwitter #gusm JCO Global Oncology

🤯

The first, evidence-based ESMO-ESTRO consensus statements to guide the combination of RT with targeted cancer therapies and immunotherapy!!! They have expected that the toxicity of combining RT with ICIs is low, particularly for PD-(L)1 inhibitors. For most combinations with